Directory Profile

Amy L. Seybert, PharmD, FASHP, FCCP, CHSE

Office: 09068 Salk Hall, 3501 Terrace St, 15261

Phone: 412-624-3545

Fax: 412-624-1850

Email: seyberta@pitt.edu

orcidpubmedLinkedIn

Amy Seybert's passion is educating the next generation of pharmacists. She is an accomplished faculty member, who has been honored as a fellow of the American College of Clinical Pharmacy and of the American Society of Health System Pharmacists. She has received multiple teaching awards including: University of Pittsburgh Chancellor’s Distinguished Teaching Award, ASHP Research and Education Foundation Pharmacy Residency Excellence Preceptor Award, AACP Rufus A. Lyman Award, and the AACP Distinguished Teaching Scholar Award. She currently serves on the ACPE Board of Directors and was on the ASHP Commission on Credentialing.

In her 15 years of practice, she developed a record of outstanding patient care and of creating programs that enhance care. Her commitment to education stimulated her to design the cardiovascular specialty residency and to advance innovative learning technologies through human patient simulation. She has now become an international expert in the application of simulation to pharmacy education and patient care. In 2013, she was the first pharmacist to become a certified healthcare simulation educator. She has published 94 manuscripts in peer-reviewed journals and has served as principal investigator on 15 grants in addition to being co-investigator on another 12 grants.

Amy Seybert is Chair of the Department of Pharmacy and Therapeutics as well as the Pharmacy Residency Administrator at UPMC. Seybert received her BS in pharmacy and her PharmD degree from the University of Pittsburgh. She completed her pharmacy residency in cardiovascular critical care at Tampa General Hospital.

Simulation Education, Interprofessional Education, Cardiovascular Medication Outcomes, Patient and Medication Safety

My research program focuses on the scholarship of education using simulation as well as enhancement of clinical patient care outcomes in cardiovascular disease and critical care with a focus on medication safety. My work in scholarship of education has led to international leadership in simulation education in pharmacy and have pioneered the use of high-fidelity human patient simulation to advance pharmacotherapy knowledge, clinical decision making, and medication safety skills in healthcare professionals. I successfully incorporated simulation into the Doctor of Pharmacy curriculum, postdoctoral training programs, and clinical practice as well as collaborated in establishing simulation as an acceptable replacement for a portion of experiential learning hours in our Accreditation Council for Pharmacy Education. I became the first pharmacist to publish on the innovative use of simulation in 2006. I have progressively documented the impact of my simulation learning design on learner satisfaction, basic physical assessment skills, foundational knowledge development, problem-solving skills, clinical decision-making ability, pharmacotherapeutic knowledge application, confidence, knowledge retention, and medication safety in clinical practice. My clinical research in cardiovascular/critical care pharmacy practice and medication safety has led to substantial patient care contributions from implementing new direct patient care practices in the Cardiac Intensive Care Unit and cardiothoracic surgery patients as well as growth of pharmacy and patient safety services throughout the UPMC Health System and beyond. My focus on clinical issues in cardiovascular and critical care medicine, and a large part of this work includes evaluating safety, efficacy, and economic outcomes of pharmacotherapy. I have documented the economic burden of new pharmacotherapeutic regimens such as antithrombin and antiplatelets. Finally, my research on computer-generated adverse alerting programs has shown improvement in approaches to detect patients at high-risk for heparin-induced thrombocytopenia.

PUBLICATIONS
Students/residents* under my direction are indicated by an asterisk.
PEER-REVIEWED ARTICLES BY RESEARCH THEME
SCHOLARSHIP OF EDUCATION USING SIMULATION
1. Seybert AL, Laughlin KK, Benedict NJ, Barton CM, Rea RS. Pharmacy student response to patient-simulation mannequins to teach performance-based pharmacotherapeutics. Am J Pharm Educ 2006, 70(3): article 48. PMID: 17136169
• First publication on the use of high-fidelity human patient simulation education within pharmacy. This paper established simulation as an active learning tool for clinical pharmacy education within pharmacy schools.
2. Seybert AL and Barton CM. Simulation-based learning to teach blood pressure assessment. Am J Pharm Educ 2007, 71(3): article 48. PMID: 17619648
• First publication on the use of high-fidelity human patient simulation for physical assessment skills in a core pharmacotherapeutics course focusing on cardiovascular pharmacotherapy. Significant improvement in learner performance and confidence was demonstrated.
3. Seybert AL, Kobulinsky LR, McKaveney TM. Innovations in Teaching Award: Human patient simulation in a pharmacotherapy course. Am J Pharm Educ 2008, 72(2); article 37. PMID: 18483603
• First publication of a pharmacotherapy knowledge and skill assessment rubric. This publication has set the standard for assessment of clinical pharmacy knowledge and decision-making skill assessment in the field.
4. McIvor WR, Seybert A, Esper S. CHF from Diastolic Dysfunction in a Patient Presenting Preoperatively for an Elective Surgery. MedEdPORTAL; 2008.
• Simulation case publication as a interprofessional team with the purpose of sharing our collaboration and case programming with the medical education field.
5. Ford DG*, Seybert AL, Smithburger PL*, Kobulinsky L, Samosky J, Kane-Gill SL. Impact of simulation-based learning on medication error rates in critically ill patients. Intens Care Med 2010;36:1526-1531. PMID: 20300731
• First publication on use of simulation education impacting medication safety with a 25% reduction in medication errors in the ICU. This publication established international leadership in education as well as in use of simulation education for direct patient care impact. This pivotal work has differentiated my work in scholarship of education as it broadens the impact of my research to direct patient care and interprofessional education.
6. Seybert AL, Kane-Gill SL. Elective course in acute care using online learning and patient simulation. Am J Pharm Educ 2011;75: article 54. (Innovations in Teaching Invitation) PMID: 21655408
• Established our innovation in education to multimodal approaches to learning.
7. Seybert AL. Patient Simulation in Pharmacy Education. Am J Pharm Educ 2011;75(9): article 187. (Simulation Supplement) PMID: 22171115
• Guest editor for the first ever simulation education supplement in AJPE. This supplement established simulation within pharmacy education as a broad reaching learning tool that has seen tremendous growth since my pioneering work over the 5 years prior to this supplement. I led the approval and development of the supplement as well as collected the team of pharmacy educators for the publication.
8. Bray BS, Schwartz CR, Odegard PS, Hammer DP, Seybert AL. Assessment in Simulation-based Learning. Am J Pharm Educ 2011; 75 (10) Article 208. (Simulation Supplement) PMID: 22345727
9. Gokhman R*, Seybert AL, Phrampus P, Darby J, Kane-Gill SL. Medication errors during medical emergencies in a large, tertiary care, academic medical center. Resuscitation 2012; 83:482-487. PMID: 22001000
10. Smithburger PL, Kane-Gill SL, Ruby C, Seybert AL. Comparing effectiveness of 3 learning strategies: Simulation-Based Learning, Problem-Based Learning, and Standardized Patients. Sim Healthcare 2012; 7(3):141-146. PMID: 22293664
• First comparison of active learning strategies in pharmacy education with simulation displaying clear advantages to other methods.
11. Seybert AL, Smithburger PL, Kobulinsky LR, Kane-Gill SL. Simulation Based Learning versus Problem Based Learning in an Acute Care Pharmacotherapy Course. Sim Healthcare 2012, Jun;7(3):162-5. PMID: 22653560
• Validation of previous work establishing simulation as having significantly more impact on knowledge in pharmacotherapy.
12. Kane-Gill SL, Post JP*, Smithburger PL, Seybert AL. “Bump”: Using a mobile app to enhance learning in simulation scenarios. Sim Healthcare 2012 Oct;7(5):326-7. PMID: 23032752
13. Smithburger PL, Kane-Gill SL, Kloet MA*, Lohr B, Seybert AL. Advancing interprofessional education through the use of high fidelity human patient simulators. Pharm Pract 2013; 11(2):61-5. PMID: 24155851
• Outlines use of high fidelity simulation in an interprofessional setting and established our culture of innovation in education throughout interprofessional education in addition to pharmacy education.
14. Kane-Gill SL, Williams EA*, Smithburger PL, Seybert AL. Tips for developing an integrated online and simulation course based on 6-years of experience. Pharmacy. 2013 Aug;1(1):34-42.
• First of several invited works as recognition of pharmacy simulation education pioneer.
15. Wang T, Seybert AL, Hu C, Wu X, Chen Y, Guan X, Shi L. Development and Evaluation of the Application-based Case Study Program. J Pharma Care Health Sys 2015, May 22 (2:3): 138-143.
• First international collaboration on learning innovations in Chinese pharmacy curricula.
16. Benedict NJ, Smithburger PL, Donihi AC, Empey PE, Kobulinsky LR, Seybert AL, Waters T, Drab SR, Lutz J, Farkas D, and Meyer SM. Blended Simulation Progress Testing for Assessment of Practice Readiness. Am J Pharm Educ 2017 Feb 25: Volume 81, Issue 1, Article 14.
17. Ong CL*, Kane-Gill SL, Kobulinsky LR, Seybert AL. Evaluation of the impact of introducing simulation-based learning in pharmacy in Singapore. Curr Pharm Teach Learn 2018 Oct;10(10):1414-1418. doi: 10.1016/j.cptl.2018.07.004. Epub 2018 Aug 8. PMID: 30527371
• This is the first paper describing international collaboration on high-fidelity simulation education. Discovering professional development needs of practicing pharmacists will assist in advancing our simulation collaborative through our international advanced practice scholar graduates.
18. Seybert AL. History of Simulation Based Learning and Vision of Future. (Pharmacy 2018, August; 6(2), Pharmacy Simulation Themed Issue, Seybert Editor)
• I was invited to serve as Special Issue Editor for this internationally focused simulation education theme. We have focused publications on international research on learning and assessment in addition to interprofessional and practitioner simulation applications. This is the first international simulation special issue in the contemporary area of scholarship.
19. Seybert AL, Kobulinsky LR. Simulation Based Learning: Development, Preparation, and Implementation. (November 2018, Pharmacy Special Issue "Simulation in Pharmacy Education and Beyond,” Seybert Editor)
20. Coons JC, Kobulinsky LR, Lutz J, Farkus D, Seybert AL. Integration of virtual electronic health record technology with simulation-based learning to advance PharmD education. Pharmacy 2018;6(4), 123. PMID: 30486520
21. Hedges A*, Johnson HJ, Kobulinsky LR, Estock JL, Eibling D, Seybert AL. Effects of Implementing Cross-training into Simulation-Based Team Training on Detection of Medication Errors. Pharmacy (Basel). 2019 Jan 19;7(1). pii: E13. doi: 10.3390/pharmacy7010013. PMID: 30669460
• This is the first interprofessional, cross-training simulation study completed and shows the impact of simulation on teamwork in the healthcare setting.
22. Coons JC, Benedict NJ, Seybert AL, Iasella CJ, Skledar SJ, Smith RB, Saul MS, Ensor CR. Pharmacotherapy Scholars Program-Intensive Longitudinal Training to Enhance Post-Graduate Readiness. Am J Pharm Educ. 2019 Nov;83(9):7327. doi: 10.5688/ajpe7327. PMID: 31871354
23. Seybert AL, Smithburger PL, Benedict NJ, Kobulinsky LR, Kane-Gill SL, Coons JC. Evidence for Simulation in Pharmacy Education. (Invited paper to JACCP 2019 Jul:2(6). https://doi.org/10.1002/jac5.1167
24. Haines ST and Seybert AL. Getting Beyond Learner Reactions: Elevating our Scholarship about Teaching and Learning. JACCP Themed Issue on Clinical Pharmacy Education and Training 2021 Feb:4(2):120-132. https://doi.org/10.1002/jac5.1379 (Served as Guest Co-Editor)
25. Smithburger PL, Kobulinsky LR, Kreider MS, Yourich BE, Seybert AL. Scalability of a remote advanced pharmacy practice experience with post graduate year one pharmacy resident preceptors. JACCP 2021 Feb;4(2):147-153. https://doi.org/10.1002/jac5.1340
• Develop and lead the first remote acute care APPE that helped to enable on time graduation as well as high quality clinical training in light of a pandemic where onsite rotations were unavailable.
26. Korenoski AJ, Ginn T*, Seybert AL. Use of an Immersive, Simulated Learning Game to Teach Pharmacy Students Clinical Concepts of Toxicology. Curr Teaching Learning 2021 May; 13(5);556-559. PMID: 33795110
27. Slain D, Goad J, Moser LR, Seybert AL. Characteristics and predictors of patient care performed by clinical department chairpersons at US schools of pharmacy. J Am Coll Clin Pharm 2021 July; https://doi.org/10.1002/jac5.1504
• This was the first study to evaluate pharmacy practice department chairs patient care responsibilities. This survey found the importance alignment with institutional goals and strategic plan as well as how that related to the responsibilities of the department chair.
28. Seybert AL. Simulation Teaching in Essentials of Pharmacy Teaching and Learning: A Practical Resource for the New Pharmacy Academic. ACCP Press (Anticipated Submission 2021)
29. Johnson HJ, Xue Y, Kobulinsky LR, Benedict NJ, Pater KS, Dhingra S, Grbach W, Miller C, Seybert AL. Assessment of Learner Stress and Anxiety during Simulation Education. (Anticipated submission 2022)
• This is the first study to assess stress and performance in a progressive readiness simulation. We were able to determine individual performance correlations within pharmacy residents providing pharmacotherapeutic recommendations.

SCHOLARSHIP OF EDUCATION: OTHER
30. Seybert AL. National Clinical Skills Competition Case: Acute Cardiovascular Disease. American Society of Health-System Pharmacists Clinical Skills Competition 2003.
31. Seybert AL. Direct Thrombin Inhibitors in Percutaneous Coronary Interventions. Princeton-Media, Continuing Education PCI Supplement 2006.
32. Seybert AL. Chancellor’s Distinguished Teaching Award 2006. University Times, November 2006.
33. Smith KM, Sorensen T, Connor KA, Dobesh PP, Hoehns JD, Marcus KB, Pass S, Seybert AL, Shapiro NL. Value of Conducting Pharmacy Residency Training – The Organizational Perspective (2008 Task Force on Residencies) Pharmacotherapy 2010;30(12):490e–510e.
34. Seybert AL, Coons JC, Kobulinsky LR. Simulated Electronic Health Record Spotlight. Lippincott Wolters Kluwer, 2017.
35. Seybert AL. ASHP Pharmacy Residency Excellence Award: Use of Simulation Training: Altering the Environment. Published in: Letters from Pharmacy Preceptors: Pearls for Success. American Society of Health System Pharmacists, 2020. https://doi.org/10.37573/9781585286461

CARDIOVASCULAR/CRITICAL CARE PHARMACY PRACTICE AND MEDICATION SAFETY
36. Seybert AL. Bivalirudin administration during percutaneous coronary intervention: Emphasis on high-risk patients. Pharmacotherapy 2002, 22(6):112S-118S. PMID: 12064568
37. Seybert AL and Coons JC*. Bivalirudin combined with provisional GP IIb/IIIa blockade is safer than heparin plus planned GP IIb/IIIa blockade during percutaneous coronary intervention. J Evid Card Med 2003, 7:173-175.
38. Rea RS*, Ansani NT, Seybert AL. Role of inhaled nitric oxide in adult heart or lung transplant recipients. Ann Pharmacother 2005, 39:913-7. PMID: 15769831
39. Coons JC*, Seybert AL, Saul MI, Kirisci L, Kane-Gill SL. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 2005, 39(10):1621-6. PMID: 16105872
• Established my antiplatelet outcomes research by defining real-world analysis of IV antiplatelets when no randomized evidence existed in the literature.
40. Rea RS*, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U, Henderson SO. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. (AMVENT Trial). Crit Care Med 2006, 34(6):1617-1623. PMID: 16614583
• Multicenter comparison of survival rates with in-hospital cardiac arrest patients receiving amiodarone, lidocaine, or both.
41. Seybert AL, Coons JC, Zerumsky K*. Treatment of heparin-induced thrombocytopenia: Is there a role for bivalirudin? Pharmacotherapy 2006, 26(2): 229-41. PMID: 16466327
• First paper to evaluate innovative use of bivalirudin in HIT establishing literature to support future study and use in the cardiothoracic surgery population.
42. Zerumsky (Watson) K*, Seybert AL, Saul MI, Lee JS, Kane-Gill SL. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention. Pharmacotherapy 2007, 27(5):647-656. PMID: 17461699
43. Kane-Gill SL, Seybert AL, Lazar J, Shatzer M, Saul MI, Kirisci L, Murali S. Resource use in decompensated heart failure by disease progression category. Congest Heart Fail 2007;13:22-28. PMID: 17268207
44. Coley KC, Saul MI, Seybert AL. Economic burden of not recognizing panic disorder in the emergency department. J Emerg Med 2007;36(1):3-7. PMID: 17933481
45. Benedict NJ*, Seybert AL, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007, 29(10):2134-2153. PMID: 18042471
• Established cardiovascular evidence-based review of pulmonary hypertension pharmacotherapy as well as outlines treatment algorithm to guide management of PAH.
46. Fanikos J, Seybert AL, Spinler S. Anticoagulation in non-ST-segment elevation acute coronary syndrome: Emerging therapeutic options. September, Formulary 2007.
47. Valko M, Cooper G, Seybert AL, Visweswaran S, Saul M, Hauskrecht M. Conditional anomaly detection methods for patient-management alert systems. Proc Int Conf Mach Learn 2008 Jul;2008.
48. Bellamy CJ*, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma 2009;66:954-958. PMID: 19276778
49. Coley KC, Saul MI, Seybert AL. Economic burden of not recognizing panic disorder in the emergency department. J Emerg Med 2009;36(1):3-7. PMID: 17933481
50. Havrilla PL*, Kane-Gill SL, Seybert AL, Verrico MM, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother 2009;43:532-536. PMID: 19261954
51. Smithburger PL*, Kane-Gill SL, Nestor BL, Seybert AL. Recent advancements and opinions in the treatment of hypertensive emergencies. Crit Care Nurse 2010;30(5):24-30. (cover article) PMID: 20889510
52. Devabhakthuni S* and Seybert AL. Oral Antiplatelet Therapy for the Management of Acute Coronary Syndromes: Defining the Role of Prasugrel. Crit Care Nurse June 30, 2010. PMID: 20592188
53. Smithburger PL*, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf 2010;33(10):879-888. PMID: 20812772
54. Smithburger PL, Seybert AL, Armahizer MJ*, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf 2010;9(5):699-712. PMID: 20377471
55. Coons JC, Plauger KM, Seybert AL, Sokos GG. Worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 2010;44(9):1496-1500. PMID: 20628043
56. Dasta JF, Boucher, BA, Brophy GM, Cohen H, Hassan E, MacLaren R, Martin S, Pass S, Seybert AL. Intravenous to oral conversion of antihypertensives: A toolkit for guideline development. Ann Pharmacother 2010;44(9):1430-47. PMID: 20702758
57. Gokhman R*, Smithburger PL*, Kane-Gill SL, Seybert AL. Pharmacokinetic rationale for combination therapy of pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010;56:686-695. PMID: 20838230
58. Smithburger PL*, Kane-Gill SL, Benedict N, Falcione BA, Seybert AL. Grading the severity of drug-drug interactions in the intensive care unit: A comparison between clinical opinion and database severity ratings. Ann Pharmacother 2010; Nov;44(11):1718-24. PMID: 209959499 (36 citations)
59. Nguyen Q*, Valizadegan H, Seybert AL, Hauskrecht M. Sample-efficient learning with auxiliary class-label information. Annual American Medical Informatics Association (AMIA) Symposium Proceedings Volume 2011, 1004-1012. PMID: 22195160
60. Harinstein LM*, Kane-Gill SL, Smithburger PL, Culley CM, Reddy VK, Seybert AL. Use of an Abnormal Laboratory Value-Drug Combination Alert to Detect Drug-Induced Thrombocytopenia in Critically Ill Patients. J of Crit Care 2012, Jun;27(3):242-9. Epub 2012 Apr 18. PMID: 22520497
61. Abel EE*, Kane-Gill SL, Seybert AL, Kellum JK. A clinical outcomes comparison between direct thrombin inhibitors for the management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy. Am J Health Syst Pharm 2012 Sep 15;69(18):1559-67. PMID: 22935938
62. Smithburger PL, Seybert AL, Kane-Gill SL. Drug-Drug Interactions in the Medical Intensive Care Unit: An Assessment of the Frequency, Severity, and the Medications Involved. Int J Pharm Pract 2012 Dec;20(6):402-8. PMID:23134100 (30 citations)
63. Armahizer MJ*, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL. Comparing DDI severity for clinician opinion to proprietary databases. ISRN Critical Care volume 2013, article ID 347346.
64. Armahizer MJ*, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 2013 Jun;28(3):243-9. PMID: 2331212
65. Anthes AM*, Harinstein LM*, Smithburger PL, Seybert AL, Kane-Gill SL. Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries. Pharmacoepidemiol Drug Saf 2013 Feb 26;22(5):510-516. PMID: 23440931
66. Kane-Gill SL, Wytiaz N*, Thompson L, Muzykovsky K, Buckley M, Cohen H, Seybert AL. A Real-World, Multicenter Assessment of Drugs Requiring Weight-Based Calculations in Overweight, Adult Critically Ill Patients. ScientificWorldJournal 2013 Nov 30;2013:909135. PMID: 24363625
67. Kloet MA*, Lohr BR*, Smithburger PL, Seybert AL, Kane-Gill SL. Progressive assessment of inpatient boxed warning prescriber adherence. J Patient Saf 2014 Mar 18. PMID: 24647270
68. Coons JC, Schwier N*, Harris J*, Seybert AL. Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opin Drug Metab Toxicol 2014 Apr; 10(4):609-20. PMID: 24555443
69. Kane-Gill SL, LeBlanc JM, Dasta JF, Devabhakthuni S, Critical Care Pharmacotherapy Trials Network. A multicenter study of the point prevalence of drug-induced hypotension in the ICU. Crit Care Med 2014 Oct;42(10): 2197-203. *Seybert AL listed as collaborator in Critical Care Pharmacotherapy Trials Network
70. Kane-Gill SL, Smithburger PL, Williams EA, Felton MA, Wang N, Seybert AL. Published Cases of Adverse Drug Reactions: Has the Quality of Reporting Improved over Time? Ther Adv Drug Saf 2015 Apr 6(2):38-44. PMID: 25922652
71. Liput SA*, Kane-Gill SL, Seybert AL, Smithburger PL. A Review of the Perceptions of Healthcare Providers and Family Members Toward Family Involvement in Active Adult Patient Care in the ICU. Crit Care Med 2016, Mar 8. PMID: 26958747
72. Cochran G, Bacci JL, Ylioja T, Hruschak V, Miller S, Seybert AL, Tarter R. Understanding Misuse Characteristics of Patients Prescribed Opioid Medications. J Am Pharm Assoc 2016 May-Jun;56(3):248-256.e6. PMID: 27053277
73. Kane-Gill SL, MacLasco AM, Saul MI, Smith TP, Kloet MA, Kim C, Anthes AM, Smithburger PL, Seybert AL. Use of Text Searching for Trigger Words in Medical Records to Identify Adverse Drug Reactions within an Intensive Care Unit Discharge Summary. Appl Clin Inform 2016;7:660-671. PMID: 27453336
74. Kloet MA, Lohr BR, Smithburger PL, Seybert AL, Kane-Gill SL. Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence. J Patient Saf 2017 Mar;13(1):25-30. PMID: 24647270
75. Altawalbeh S*, Saul MI, Seybert AL, Thorpe J, Kane-Gill SL. Comparing the Impact of Intensive Care Unit Drug Use on Hospital Costs over 4-Years to a Decade Later. J Crit Care. 2018 Apr;44:77-81. [Epub 2017 Oct 19] doi: 10.1016/j.jcrc.2017.10.029. PMID: 29073536
76. Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, Hruschak V, Chickering S, Kincman J, Jaber A, Tarter R. A Community Pharmacy Intervention for Opioid Medication Misuse: A Pilot Randomized Clinical Trial. J Am Pharm Assoc 2018 Jul-Aug;58(4):395-403. PMID: 29691197
77. Gray MP*, Dziuba G, Quach K, Wong A, Smithburger PL, Seybert AL, Kane-Gill SL. Assessing Adverse Drug Reactions from Psychotropic Medications Reported to the FDA in Older Adults. Am J Geriatr Psychiatry. 2019 Feb;27(2):181-185. doi: 10.1016/j.jagp.2018.09.013. [Epub 2018 Sep 27.] PMID: 30503701
78. Cochran G, Chen Q, Field C, Seybert AL, Hruschak V, Jaber A, Gordon A, Tarter R. A Community Pharmacy-Led Intervention for Opioid Medication Misuse: A Small-Scale Randomized Clinical Trial. Drug Alcohol Depend. 2019 Dec 1;205:107570. doi: 10.1016/j.drugalcdep.2019.107570. Epub 2019 Oct 22. PMID: 31689641
79. Rice M*, Lear A*, Kane-Gill SL, Seybert AL, Smithburger PL. Pharmacy Personnel’s Involvement in Transitions of Care of Intensive Care Unit Patients: A Systematic Review. J Pharm Pract. 2020 Apr 1:897190020911524. doi: 10.1177/0897190020911524. [Epub ahead of print] PMID: 32233830
80. Korenoski A, Li A*, Kane-Gill SL, Seybert AL, Smithburger PL. Pharmacologic Treatment of Delirium in the ICU: A Review of the Literature. J Intensive Care Med. 2020;35(2):107-17. PMID: 30309280
81. Pruskowski J, Berenbrok L, Ruby-Scelsi CM, Seybert AL, Handler S. Medication Related 30-day Rehospitalizations in Palliative Care Patients. JACCP 2020 June:3(6). https://doi.org/10.1002/jac5.1289
82. Xue Y, Hu Z, Jing Y, Seybert A, Wang j, Xie X. Efficacy Assessment of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention by Data Mining and Machine-Learning Decision Tree Approaches. J Clin Pharm and Ther. 2020 Jul 6. Doi: 10.1111/jcpt.13172 PMID 3267223
83. Tarter RE, Kirisci L, Cochran G, Seybert A, Reynolds M, Vanyukov M. Forecasting Opioid Use Disorder at 25 Years of Age in 16-Year-Old Adolescents. J Pediatrics 2020 Oct;225: 207-213e1. PMID: 32652077
84. Rice M, Lear A, Kane-Gill S, Seybert AL, Smithburger PL. Pharmacy Personnel’s Involvement in Transitions of Care of Intensive Care Unit Patients; A Systematic Review. J Pharm Pract 2021 Feb;34(1):117-126. PMID: 32233830
85. Moreland-Head LN*, Coons JC, Seybert AL, Gray MP, Kane-Gill SL. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. J Cardiovasc Pharmacol Ther 2021 Jul;26(4):341-348. PMID: 33403858

CARDIOVASCULAR/CRITICAL CARE PHARMACY PRACTICE AND MEDICATION SAFETY: OTHER
86. Chung D* and Seybert AL. Does chronic amiodarone cause myopathy? Antidote 2000, 5(2):3
87. Seybert AL. Is it time to replace unfractionated heparin in PCI? Special Report, Supplement to Pharmacy Practice News May 2002.

BOOK CHAPTERS
88. Seybert AL. Ventricular Tachycardia. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 2nd edition, Stamford, CT: Appleton & Lange, 2000.
89. Seybert AL and Rice T. Pulmonary Embolism. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 2nd edition, Stamford, CT: Appleton & Lange, 2000.
90. Seybert AL. Ventricular Tachycardia. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 5th edition, New York, NY: McGraw-Hill, 2002.
91. Seybert AL and Rice T. Pulmonary Embolism. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 5th edition, New York, NY: McGraw-Hill, 2002.
92. Seybert AL. Ventricular Tachycardia. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 6th edition, New York, NY: McGraw-Hill, 2005.
93. Seybert AL and Rice T. Pulmonary Embolism. In: Schwinghammer TL, ed. Pharmacotherapy Casebook: A Patient-Focused Approach. 6th edition, New York, NY: McGraw-Hill, 2005.
94. Seybert AL and Coons JC. Atrial Arrhythmias. In: Cardiovascular Pharmacotherapy: A Point-of-care Guide. American Society of Health System Pharmacists, 2010.

AWARDS AND HONORS
2021 American Association of Colleges of Pharmacy (AACP), Distinguished Teaching Scholar Award
2019 Journal of the American College of Clinical Pharmacy (JACCP) Outstanding Reviewer
2019-2020 ACC Academic Leaders Network (ALN) program
2018 AACP Lyman Award, “Blended Simulation Progress Testing for Assessment of Practice Readiness”
2018 Phi Lambda Sigma Chapter Alumni of the Year
2017 AACP Award for Excellence in Assessment, Blended Simulation Progress Testing for Assessment of Practice Readiness
2017 American Society of Health System Pharmacists (ASHP) Residency Excellence Award: Program Nominee
2014 First Pharmacist Certified Simulation in Healthcare Educator (CHSE)
2012 ASHP Visiting Leaders Program, UPMC Residency Programs
2012 Finalist for “The Simmy Award” at the International Meeting for Simulation in
Healthcare Meeting, San Diego, CA
2011 Society of Critical Care Medicine (SCCM), Clinical Pharmacy and Pharmacology Section Technology Patient Safety: Award for using simulation-based learning to reduce medication errors in critically ill patients
2011 American College of Clinical Pharmacy, Fellow (FCCP)
2011 American Society of Health System Pharmacists, Fellow (FASHP)
2010 AACP, Innovations in Teaching, Honorable Mention
2010 Rho Chi Innovations in Teaching Award, University of Pittsburgh School of Pharmacy
2009 Pharmacy Residency Excellence Preceptor Award, ASHP Research and Education Foundation
2008 Residency Preceptor of the Year, University of Pittsburgh School of Pharmacy
2007 American Association of Colleges of Pharmacy, Faculty Delegate
2006 Academy of Students of Pharmacy, Faculty of the Year
2006 University of Pittsburgh Chancellor’s Distinguished Teaching Award
2006 Rho Chi Innovations in Teaching Award, University of Pittsburgh School of Pharmacy
2006 AACP, Innovations in Teaching, Honorable Mention
2005 Phi Lambda Sigma
2004 Heart Failure Initiative: Improving Angiotensin-Converting Enzyme (ACE) Inhibitor Use for Patients with Left Ventricular Systolic Dysfunction
UPMC Performance Improvement Award, 5th Place
2002 Congestive Heart Failure Disease Management Team UPMC Performance Improvement Award, 5th Place
2001-2002 AACP, University of Pittsburgh School of Pharmacy Faculty Delegate
2000 Academy of Students of Pharmacy, Faculty of the Year
1999-2000 AACP, University of Pittsburgh School of Pharmacy Faculty Delegate

INVITED PRESENTATIONS
SELECT INTERNATIONAL/NATIONAL/LOCAL PRESENTATIONS
SCHOLARSHIP OF EDUCATION USING SIMULATION
1. “Simulation Based Learning in Pharmacy Education” –5th Annual Safar Symposium, University of Pittsburgh Safar Center for Resuscitation Research, Pittsburgh, PA, May 31, 2007.
2. “Integrating Human Patient Simulator Technology into the Pharmacy and Nursing Curricula”-American Association of Colleges of Pharmacy Annual Meeting and Seminars, Orlando, FL, July 16, 2007.
3. “Introducing Human Patient Simulation to Pharmacy”-American Society of Health System Pharmacists, Orlando, FL, December 9, 2008.
4. “Introduction to Simulation: Application in Community Pharmacy Practice”-Cardinal Health Retail Business Conference, Washington, DC, July 29, 2009.
5. “Human Patient Simulation in Pharmacy Education”-Cedarville University, September 18, 2009.
6. “Cardiovascular Pharmacotherapy Update: Ready, Set...Practice!”-University of Pittsburgh School of Pharmacy Fall Continuing Education Series, Pittsburgh, PA, November 1, 2009.
7. “Managing Pharmacotherapeutic Challenges: Learning Through Simulation”- Society of Critical Care Medicine’s 39th Critical Care Congress, Miami, FL, January 9, 2010.
8. “Simulation in Pharmacy Education”- International Meeting on Simulation in Healthcare, Phoenix, AZ, January 25, 2010.
9. “Safar Symposium on Simulation”- Peter M. Winter Institute for Simulation Education and Research (WISER), June 2, 2010.
10. “Portfolios in Experiential Education”- American Association of Colleges of Pharmacy Annual Meeting 2010, Seattle, WA, July 2010.
11. “Workshop with the American Journal of Pharmacy Education Editorial Board”- American Association of Colleges of Pharmacy Annual Meeting 2010, Seattle, WA, July 2010.
12. “Nuts and Bolts of Integrating Human Patient Simulation into the PharmD Curriculum”- American Association of Colleges of Pharmacy Annual Meeting 2010, Seattle, WA, July 2010.
13. “Progressive Learning Strategies for Foundations in Critical Thinking”- American Association of Colleges of Pharmacy Annual Meeting 2010, Seattle, WA, July 2010.
14. “Simulation Based Learning to Enhance Practice Skills: Trials and Triumphs”- American Association of Colleges of Pharmacy Annual Meeting 2010, Seattle, WA, July 2010.
15. “Barriers, Hurdles, and Lessons Learned in the Scholarship of Teaching and Learning”- American College of Clinical Pharmacy, Austin, TX, October 2010.
16. “Critical Care PRN Focus Session—Adverse Drug Events in the ICU: Learn Using High Fidelity
Patient Simulation Cases- Drug-Induced Adverse Event Case 1”- American College of Clinical Pharmacy, Pittsburgh, PA, October 2011.
17. “Simulation in Pharmacy Education and Pharmacy Practice”- American Association of Colleges of Pharmacy, Webinar, January 25, 2012.
18. “Experiential Education Section: Interprofessional High-fidelity Simulations in the Curriculum: Two Innovations for the Price of One!”- American Association of Colleges of Pharmacy Annual Meeting 2012, Kissimmee, FL, July 2012.
19. “University of Pittsburgh School of Pharmacy: Overview of Clinical Pharmacy”- Shanghai Pharmacy Association, Shanghai, China, May 2, 2013.
20. “Simulation Preceptorship”- Midwestern University College of Pharmacy, Chicago, IL, June 14, 2013.
21. “Clinical Pharmacy in a Large US Academic Healthcare System”- Peking University, Beijing, China, May 19, 2014.
22. “Clinical Pharmacy in a Large US Academic Healthcare System”- Second Military University, Shanghai, China, May 20, 2014.
23. “Clinical Pharmacy in a Large US Academic Healthcare System”- National Clinical Pharmacy Program, Changhai Hospital, Shanghai, China, May 21, 2014.
24. “Simulation in Pharmacy Education”-European Association of Hospital Pharmacists 20th Annual Congress, Hamburg, Germany, March 2015.
25. “Assessing Effects of Cross-Training on Teamwork and Collaboration of Medical Teams”- VA Pittsburgh Healthcare System Office of Academic Affiliations Advanced Fellowships Conference, Pittsburgh, PA, May 2015.
26. “Simulation in Pharmacy Education: ACCP Teaching and Learning Academy Programming”-American College of Clinical Pharmacy, Phoenix, AZ, April 10, 2016.
27. “Simulation in Pharmacy Education: From Theory to Impact”- University of Florida Department of Pharmacotherapy and Translational Research Seminar Series, Gainesville, FL, April 14, 2016.
28. “University of Pittsburgh School of Pharmacy Residency Research Day”- University of Pittsburgh School of Pharmacy, Pittsburgh, PA, June 2, 2016.
29. “Practical Application of Simulated Learning Environments and Virtual Worlds: Benefits of Multimodality Simulation in Pharmacy Education”- American Association of Colleges of Pharmacy Annual Meeting, Anaheim, CA, July 26, 2016.
30. “Integration of Virtual Electronic Health Record Technology into a Core Therapeutics Course for PharmD Students”- American Association of Colleges of Pharmacy Annual Meeting, Anaheim, CA, July 27, 2016.
31. “Learning is NOT a Spectator Sport: Active Learning in Pharmacy Education: Stepping Up Education through Simulation”-American Association of Colleges of Pharmacy Annual Meeting, Teacher’s Seminar, Nashville, TN, July 15, 2017.
32. “Technology in Pharmacy Education and Learning SIG: Case Studies and Application of Emerging Technologies”- American Association of Colleges of Pharmacy Annual Meeting, Teacher’s Seminar, Nashville, TN, July 16, 2017.
33. “Simulation Education in Health Science Education and Practice”- Texas Tech University Health Sciences Center School of Pharmacy, August 9, 2017.
34. “Enhancing Residents’ Training with Simulation: Knowledge, Assessment and Research”- National Pharmacy Preceptors Conference, Washington, D.C., August 19, 2017.
35. “Hypertension Pharmacotherapy: Educating with Simulation,” Clinical Pharmacist Pharmacy Service Skills International Forum, Shanghai, China, August 27, 2020.
36. “2020 and Beyond: How a Nimble Approach to APPE Drives Agile Patient Centered Care Experiences,” ACCP Annual Meeting, October 27, 2020.
37. “Academic Leadership Panel: Who Does What in Academic Leadership at Pitt?” Sponsored by the Office of the Provost, October 12, 2021.

CARDIOVASCULAR/CRITICAL CARE PHARMACY PRACTICE AND MEDICATION SAFETY
38. “Current Strategies in Antihypertensive Therapies”- University of Pittsburgh School of Pharmacy: 39th Annual Spring Continuing Education Seminar, Pittsburgh, PA. April 19, 1998.
39. “American College of Sports Medicine Exercise Specialist Workshop: Pharmacology”- American College of Sports Medicine Exercise Specialist Summer Workshop, June 1998.
40. “A Practical Update on Managing Arrhythmias: Special Challenges: Critical Dose, Narrow Therapeutic Index and Generic Substitution”- National continuing education program, Philadelphia, PA, October 31, 1998.
41. “Glycoprotein IIb/IIIa Platelet Receptor Inhibitor Overview”
• Rhode Island Society of Hospital Pharmacists, Providence, RI, February 23, 1999.
• Jefferson County Academy of Pharmacy, 37th Annual Seminar, Steubenville, OH, March 7, 1999.
• New England Council of Hospital Pharmacists, 46th Annual Spring Seminar, Boston, MA, May 11, 1999.
• National Council of Perfusionists, Pittsburgh, PA, May 19, 2000.
42. “Saturday Morning Mini Series” on “Complex Drug Therapy in Cardiac and Renal Patients”- Three Rivers Chapter of American Association of Critical Care Nurses, Pittsburgh, PA. April 10,1999.
43. “Clinical Cardiology Updates: Acute Coronary Syndromes: A Pharmaceutical Prospective”– West Virginia University Hospitals and Clarksburg, WV, VAMC, May 4, 1999.
44. Chartwell Nursing Education Series-“Inotropic Agents in the Home Setting”- University of Pittsburgh, Johnstown, PA, June 29, 1999.
45. “Heart Care Partnership: A Strategy to Improve Coronary Artery Disease Outcomes for the 21st Century”-University of Pittsburgh Medical Center Health System, Pittsburgh, PA, July 20, 1999.
46. “Acute Coronary Syndromes: Glycoprotein II/IIIa Platelet Receptor Inhibitors”- Regional Clinical Pharmacy Meeting, Albany, NY, September 13, 1999.
47. “Pharmacoeconomics of Acute Coronary Syndrome Pharmacotherapy”- Southern California Managed Care Pharmacists/Clinical Pharmacists, Los Angeles, CA. September 18, 1999
48. “Acute Pharmacotherapy of Dysrhythmias”- Allegheny Association of Emergency Medicine Nurses, Pittsburgh, PA. October 21, 1999.
49. “Update on Intravenous Amiodarone Therapy”- Western Pennsylvania Nurses Association, Pittsburgh, PA, January 26, 2000.
50. “Drug Protocols in Advanced Cardiac Life Support”- Pennsylvania Society of Health System Pharmacists, Pittsburgh, PA, March 23, 2000.
51. “Evaluating the Evidence: Low Molecular Weight Heparins in Clinical Practice”- Ohio Society of Hospital Pharmacists, Columbus, OH, September 12, 2000.
52. “Unstable Angina/NSTEMI Guidelines: Pharmacotherapy”- Alabama Society of Health System Pharmacists, Birmingham, AL, September 13, 2000.
53. “Acute Coronary Syndromes: Focus on Glycoprotein IIb/IIIa Antiplatelet Agents”- University of Alabama, AL, September 14, 2000.
54. “New Evidence for the Management of Acute Coronary Syndromes”- American Society of Health System Pharmacists Midyear Meeting, Las Vegas, NV, December 4, 2000.
55. “Update on Acute Coronary Syndromes: Overview of New ACC/AHA Guidelines for Unstable Angina”–Third Annual Forum for Pharmacy Directors, Pittsburgh, PA, February 24, 2001.
56. “Chronic Pharmacotherapy of Cardiovascular Disease”–Altoona Family Practice Grand Rounds, Altoona Hospital, Altoona, PA, May 15, 2001.
57. “Evaluating the Evidence: Low Molecular Weight Heparins in Clinical Practice”- Ohio Society of Health System Pharmacists, Columbus, OH, September 12, 2000.
58. “Unstable Angina/NSTEMI Guidelines: Pharmacotherapy”- Alabama Society of Health System Pharmacists, Birmingham, AL, September 13, 2000.
59. “Acute Coronary Syndromes: Evolving Evidence”- University of Alabama Cardiovascular Grand Rounds, Birmingham, AL, September 14, 2000.
60. “TACTICS: Announcement of Trial Results”- American Society of Health System Pharmacists Midyear Meeting, Las Vegas, NV, December 3, 2000.
61. “Bivalirudin Administration During Percutaneous Coronary Intervention: Emphasis on High-Risk Patients” - The Medicine’s Company Consultant Meeting, Boca Raton, FL, January 11, 2002.
62. “LMWH Horizons: New Uses, New Evidence, New Agents”
• West Virginia Society of Health System Pharmacists, Charleston, WV, March 21, 2002.
• South-Central Alabama Society of Health System Pharmacists, Florence, AL, April 2, 2002.
• Regional Pharmacy Continuing Education Program, Birmingham, AL, April 25, 2002.
63. “Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy”– South Central Louisiana Society of Health System Pharmacists Annual Meeting, Baton Rouge, LA, April 30, 2002.
64. “New Drug Update: A Focus on Cardiovascular Agents”
• University of Pittsburgh School of Pharmacy Alumni Weekend, Seven Springs, PA, June 8, 2002.
• University of Pittsburgh Medical Center, Cardiopulmonary Nursing Workshop, Pittsburgh, PA, April 10, 2003.
65. “Update on Current Issues in Cardiac Pharmacology”– UPMC Presbyterian - UPMC Shadyside Cardiothoracic Nursing, Innovations 2002: A Cardiothoracic Nursing Symposium, Pittsburgh, PA, September 9, 2002.
66. “Comprehensive Management of Cardiovascular Disease”– University of Pittsburgh School of Pharmacy Fall Continuing Education Seminar, Pittsburgh, PA, November 17, 2002.
67. “Clinical Pharmacy” – University of Pittsburgh School of Pharmacy, Rho Chi Honor Society Pharmacy Overview, Pittsburgh, PA, November 15, 2002.
68. “Update on Drug Therapy: Focus on Common Medical Problems in Oncology Patients-Update on the Pharmacotherapeutic Management of Hypertension” – Cooper Conference Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, March 13, 2003.
69. “Heart Failure: What’s new in treatment?” – University of Pittsburgh Medical Center Heart Failure Awareness Week, patients with heart failure, Pittsburgh, PA, March 15, 2003.
70. “Pharmacology Update for Advanced Practice Clinicians-Update on Management of Hyderlipidemias and Hypertension”– University of Pittsburgh School of Nursing, Pittsburgh, PA, April 4, 2003.
71. “Managing Cardiovascular Risk Factors”– University of Pittsburgh School of Pharmacy 45th Annual Paul J. Wurdack Fall Continuing Education Seminar, Pittsburgh, PA, November 16, 2003.
72. “Updates on New Dyslipidemia Therapies”– Regional Pharmacists Program, Pittsburgh, PA, November 18, 2003.
73. “The Great Debate: Management of Hyperlipidemia”– Regional Physician, Nursing, and Pharmacy meeting, Pittsburgh, PA, December 10, 2003.
74. “Management of Heart Failure” – University of Pittsburgh Medical Center Heart Failure Awareness Week, Pittsburgh, PA, February 10, 2004.
75. “Heart Failure Medications”- Community Awareness Program, University of Pittsburgh Medical Center, Saturday program for patients, Pittsburgh, PA, February 21, 2004.
76. “Management of Heart Failure” – University of Pittsburgh Medical Center, Cardiovascular Nursing Certification Program, Pittsburgh, PA, March 3, 2004.
77. “Cardiac Pharmacology”– University of Pittsburgh Medical Center Health System, Shadyside and Presbyterian University Hospital Nursing Program, Pittsburgh, PA, March 25, 2004.
78. “The Great Debate: Phosphodiesterase 5 Inhibitors”– Regional Physician meeting, Pittsburgh, PA, May 20, 2004.
79. “Cardiac/Vascular Nursing Certification Review Course”- University of Pittsburgh Medical Center Health System, Shadyside and Presbyterian University Hospital Nursing Program, Pittsburgh, PA, May 19, 2005.
80. “High Risk Cardiovascular Patients” – Women’s Physician Health Promotion Grand Rounds, Dallas, TX, August 5, 2005.
81. “Optimizing Therapy in Cardiovascular Patients” – Taiwanese Asian Physician Association, Cleveland, OH, August 13, 2005.
82. “Angiotensin Converting Inhibitors in Heart Failure” – University of Cincinnati Cardiovascular/Nephrology Grand Rounds, Cincinnati, OH, September 14, 2005.
83. “Patient Safety Symposium-Heparin-Induced Thrombocytopenia”- Pittsburgh Regional Continuing Education Program, Pittsburgh, PA, November 28, 2005.
84. “Update on Heart Failure Guidelines” – Butler Veteran’s Administration Grand Rounds, Butler, PA, January 10, 2006.
85. “Heparin-Induced Thrombocytopenia and Direct Thrombin Inhibitors”– Cleveland Society of Health System Pharmacists, Cleveland, OH, January 26, 2006.
86. “Cardiopulmonary Lecture Series-Acute Myocardial Infarction”- University of Pittsburgh Medical Center Health System, Shadyside and Presbyterian University Hospital Nursing Program, Pittsburgh, PA, January 31, 2006.
87. “Cardiac/Vascular Nursing Certification Review Course”- University of Pittsburgh Medical Center Health System, Shadyside and Presbyterian University Hospital Nursing Program, Pittsburgh, PA, February 8, 2006.
88. “Update on Antithrombin Therapy During Percutaneous Coronary Interventions”– National Continuing Education Teleconference Series, March 2006.
89. "Anticoagulation Therapy 2006: New Challenges for Health Systems"- Southeastern Chapter, Pennsylvania Society of Health-System Pharmacists, York, PA, September 14, 2006.
90. "Bivalirudin in Comparison to Unfractionated Heparin in Percutaneous Coronary Interventions at UPMC"- Northwestern Chapter, Ohio Society of Health-System Pharmacists, Toledo, OH, November 9, 2006.
91. “Providing Chronic Care for Patients with Diabetes and Cardiovascular Disease”- Spring Continuing Education Seminar, University of Pittsburgh School of Pharmacy and Peter M. Winter Institute for Simulation Education and Research, April 15, 2007. (Program Coordinator and Speaker)
92. “Evolving Anticoagulation Concepts in Acute Coronary Syndromes”- Long Island Society of Health System Pharmacists, Woodbury, NY, May 22, 2007.
93. “Contemporary Antithrombin Pharmacotherapy”- Southeast Regional Cardiac Catherization Laboratory Directors Meeting, Greenville, SC, August 23, 2007.
94. “Bivalirudin Outcomes at the University of Pittsburgh Medical Center”- Veteran’s Administration Regional Pharmacy Directors Conference, Destin, FL, October 4, 2007.
95. “Heparin Induced Thrombocytopenia”- New York Society of Physician Assistants, Syracuse, NY, October 14, 2007.
96. “Evolving Anticoagulation Concepts in Acute Coronary Syndromes”- Cleveland Society of Health System Pharmacists, Cleveland, OH, October 23, 2007.
97. “Evolving Anticoagulation Concepts in Acute Coronary Syndromes”- American Society of Health System Pharmacists, Las Vegas, NV, December 3, 2007.
98. “Commonly Used Antihypertensive Agents in the Stroke Patient”- University of Pittsburgh Medical Center, Stroke Institute, How to Excel in Acute Stroke Management Conference, Pittsburgh, PA, April 18, 2008.
99. “Updates in Anticoagulation Therapy”- Bayhealth Pharmacy Continuing Education Conference, Dover, DE, October 22, 2008.
100. “Comparison of Outcomes for Patients Receiving Bivalirudin and Unfractionated Heparin in Percutaneous Coronary Intervention”- December 4, 2006, The Medicine’s Company Advisory Board.
101. “The Angiomax Value Proposition: Forecasting the Future” Meeting, Anaheim, CA, May 2010.
102. “An Overview of Antiplatelets, Antithrombins, and Anticoagulants”- American College of Cardiology, Educational Conference West, Pittsburgh, PA, May 14, 2010.
103. “Pulmonary Hypertension Pharmacotherapy”- American Society of Health System Pharmacy, Anaheim, CA, December 2010.
104. “Meeting the Challenges of Contemporary PAH Management”- Academy of Managed Care Pharmacy 24th Annual Meeting 2012, San Francisco, CA, April 2012.

Grant Total: $450,000. “Prescription opioid misuse: Pharmacist-delivered intervention at point of service,” National Institute on Drug Abuse, 2017, Co-Investigator, Cochran GT, Principal Investigator.
Grant Total: $35,000. Critical Care Pharmacy Residency. Educational Grant, Amgen, Inc. 2006, Principal Investigator
Grant Total: $3,000. “Chancellor’s Distinguished Teaching Award 2006.” University of Pittsburgh, Principal Investigator.
Grant Total: $10,000. “Young Pharmacist Award.” The Society of Hospital Pharmacists in Australia, 2007, Co-Investigator.
Grant Total: $22,000. “Helpful Hands for Healthy Hearts.” NitroMed Pharmaceuticals, 2007, Principal Investigator.
Grant Total: $21,097. “Simulation Based Learning and Online Learning to Enhance Problem Solving Skills in Acute Care Pharmacotherapy.” University of Pittsburgh Provost’s Advisory Council on Instructional Excellence Innovation in Education Award, 2008, Principal Investigator.
Grant Total: $95,000. “CARE PACT: Collaborating and Advancing Relationships: Pharmacist Advocates in Care,” Jewish Healthcare Foundation, 2010, Co-Investigator.
Grant Total: $40,000. “Pharmacy Practice Residency Expansion Grant,” ASHP Foundation, 2011, Residency Program Director of Pharmacy, Principal Investigator.
Grant Total: $45,000. “Pharmacy Practice Residency Expansion Grant,” ASHP Foundation, 2012, Residency Program Director, Critical Care Pharmacy.
Grant Total: $24,450. “Transforming the role of the hospital pharmacist to improve patients' access, adherence, and self-management of medication after discharge,” UPMC Beckwith Institute Clinical Transformation Grant, 2013, Co-Principal Investigator.
Grant Total: $14,450. “Evidence-Based Healthcare: Interprofessional, Learner-Focused Small Groups in Large Lecture Courses in Dentistry and Pharmacy,” University of Pittsburgh Provost’s Advisory Council on Instructional Excellence Innovation in Education Award, 2013, Co-Principal Investigator.
Grant Total: $1000. “Impact of Pharmacy-Driven Management of Diabetes Mellitus in and Underserved Patient Population,” Alliance for Patient Medication Safety, 2017, Residency Program Chair
Grant Total: $14,380. “Relationship of Cytokine Gene Polymorphism to Cardiothoracic Organ Transplant Outcome," Co-Investigator. University of Pittsburgh Central Research Development Fund, Small Grants Program, 2002.
Grant Total: $30,890. “Frequency of Suboptimal HDL-C Levels in Statin Treated Patients with Unstable Angina at the University of Pittsburgh Medical Center.” KOS Pharmaceuticals, 2008, Principal Investigator.
Grant Total: $5,000. “Clinical Outcomes Comparison of Direct Thrombin Inhibitors for the Management of Heparin-Induced Thrombocytopenia in Patients Receiving Hemodialysis.” ASHP Foundation for the New Practitioners Resident Practice-Based Research Grant Program, 2008, Residency Director and Research Mentor.
Grant Total: $110,000. "Heparin-induced Thrombocytopenia Detection: Use of a Computerized Anomaly Detection Program to Improve Patient Safety," National Institute of Health R21 Grant Award, 2006, Co-Investigator.
Grant Total: $250,000. "Using Medical Records Repositories to Improve the Alert System Design," National Library of Medicine, National Institute of Health R01 Grant Award, 2009, Co-Investigator.

View CV

In some browsers, the CV link may not automatically open. You may right-click on the link to open in a new tab to view the CV file.